Patiromer for Hyperkalemia Recommended for Marketing in EU

The potassium-binding agent had been seen to safely control mild to moderate hyperkalemia in a phase 2 trial of patients with diabetic nephropathy.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s